Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized patients with COVID-19.Methods: In this randomized, controlled, open-label, platform trial, we randomly assigned patients ≥18 years hospitalized with COVID-19 pneumonia to receive either camostat mesylate (CM) (c...

Full description

Bibliographic Details
Main Authors: M. Karolyi, E. Pawelka, S. Omid, F. Koenig, V. Kauer, B. Rumpf, W. Hoepler, A. Kuran, H. Laferl, T. Seitz, M. Traugott, V. Rathkolb, M. Mueller, A. Abrahamowicz, C. Schoergenhofer, M. Hecking, A. Assinger, C. Wenisch, M. Zeitlinger, B. Jilma, A. Zoufaly
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
tmprss2
SARS-CoV-2
high-dose lopinavir/ritonavir
camostat mesylate
mortality
WHO scale
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.870493/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.870493/full

Similar Items